Cargando…
Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection
Baseline resistance-associated substitutions (RASs) have variable impacts in clinical trials but their prevalence and impact in real-world patients remains unclear. We performed baseline resistance testing using a commercial assay (10% cutoff) for 486 patients treated with LDV/SOF or SMV/SOF, with o...
Autores principales: | Wang, Gary P., Terrault, Norah, Reeves, Jacqueline D., Liu, Lin, Li, Eric, Zhao, Lisa, Lim, Joseph K., Morelli, Giuseppe, Kuo, Alexander, Levitsky, Josh, Sherman, Kenneth E., Frazier, Lynn M., Ramani, Ananthakrishnan, Peter, Joy, Akuskevich, Lucy, Fried, Michael W., Nelson, David R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5816647/ https://www.ncbi.nlm.nih.gov/pubmed/29453451 http://dx.doi.org/10.1038/s41598-018-21303-2 |
Ejemplares similares
-
Severe Steroid-responsive Skin Disorders Related to Ledipasvir and Sofosbuvir for HCV
por: Tadokoro, Tomoko, et al.
Publicado: (2017) -
Ventricular Tachycardia as a Complication of Ledipasvir and Sofosbuvir Treatment for HCV Infection
por: Nirei, Kazushige, et al.
Publicado: (2017) -
The effectiveness of oral antiviral (Sofosbuvir/Ledipasvir) in treating children with HCV infection
por: Alkaaby, Ban Adil, et al.
Publicado: (2018) -
Lower response to simeprevir and sofosbuvir in HCV genotype 1 in routine practice compared with clinical trials
por: Yee, Brittany E, et al.
Publicado: (2016) -
New-Onset Diabetes Mellitus With Exposure to Ledipasvir and Sofosbuvir
por: Premji, Resmi, et al.
Publicado: (2015)